Diabetes mellitus is the most common cause of blindness in working age populations worldwide. While much of the focus for public health has been on secondary prevention in sight-threatening diabetic retinopathy, the cornea, including its epithelium and nerves, represents a major site of damage by chronic hyperglycemia. On injury, the diabetic cornea exhibits a delayed wound-healing response, as well as an altered ocular surface immune response. This suggests a potential association between the dysfunctional wound healing response and altered inflammation on the ocular surface. However, the presence of potential confounders makes this association difficult to investigate in human epidemiological studies. Thus, we turn to animal diabetic models for a better understanding.
In this review, 20 original studies, published between 2008 and 2018, describe in vivo and in vitro models of diabetic cornea disease. We compared different models of diabetic cornea wound healing and discussed the relative strengths and drawbacks of each model. A number of molecular and cellular components involved in the corneal wound healing response that are altered in the presence of diabetes have been identified in the reviewed studies. Particularly, altered corneal epithelial protein concentrations of lumician and occludin were detected in diabetic eyes compared with controls. Additionally, the importance of IL-1β in modulating the inflammatory response after corneal injury in patients with diabetes and controls was further elucidated. Meanwhile, abnormal P2×7 receptor localization and decreased corneal sub-basal nerve density in diabetic eyes were shown to contribute to altered corneal nerve signaling after injury and thus affecting the wound healing response. Finally, the discovery of the therapeutic effects of topically administered aloe vera, Serpine 1, Resolvin D1 (RvD1), pigment epithelium-derived factor (PEDF) and Pro-His-Ser-Arg-Asn in diabetic animal models of cornea epithelial and nerve injury provide encouraging evidence for the future availability of effective treatment for diabetic keratopathy.
- diabetes, cornea, epithelial wound healing
- animal models
- in vitro models
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
Diabetes mellitus (DM) is an important chronic disease, affecting more than 342 million people worldwide, with a trend of increasing prevalence in the last decade. Patients with DM are at a higher risk of developing ocular complications and account for the major cause of acquired blindness in working-age populations.1–3 In recent years, much of the focus for public health system worldwide has been on secondary prevention of sight-threatening diabetic retinopathy. While in contrast, there is relatively less attention to diabetic keratopathy, it is a common complication, affecting more than half of patients with DM worldwide.
Diabetes keratopathy is characterized by ocular surface disease and impaired corneal epithelial wound healing. Previous studies have indicated molecular changes occurred on the ocular surface, including higher tear levels of insulin-like growth factor-binding protein 1, accumulation of advanced glycation end products (AGE) and loss of disruption of tight junctions on the corneal epithelium. It is also known that diabetic status is associated with alterations in the systemic cellular adaptive immune system. This in turn results in high serum levels of tumor necrosis factor-α, interleukin (IL)-6 and IL-8 in patients with diabetes compared with controls.4 Currently, the impact of this altered immune response in patients with diabetes on ocular surface wound healing remains unclear.
We performed a systematic review of recent published literature, focusing on the association between corneal injury and re-epithelialization in the context of animal models of sustained hyperglycemia. We highlighted the different diabetic animal models used and methods of corneal injury. The molecular changes involved in corneal injury caused by hyperglycemia and those involved in the recovery of corneal epithelium and corneal nerves are discussed. Potential drugs or drug targets discovered from the reviewed studies are also introduced.
Materials and methods
An Entrez PubMed search was conducted on 1 January 2019 using the search terms ‘diabetes’, ‘cornea’ and ‘injury’. Only articles published within 10 years and written in English language were included. With this criteria, 37 articles were identified. The resulting articles were then manually curated for relevance by YB and KCS. For example, papers concerning diabetes (both type 1 and 2), cornea, injury and recovery, corneal re-epithelialization were considered as relevant. Furthermore, only original articles were included, while review papers and meta-analyses were excluded. This produced a list of 14 of relevant articles. Additionally, we identified six studies in the references of our finalized results to give a total of 20 papers for our review.
In total, 20 papers were reviewed after manual curation. For analysis, we grouped our discussion of the finalized papers into the following headings: (1) models of the diabetic cornea; (2) models of corneal injury; (3) mechanisms of impaired wound healing investigated; and (4) treatments investigated to improve wound healing outcomes.
Modeling the diabetic cornea
Established animal models of type 1 (insulin deficiency) and type 2 (insulin resistance) diabetes enable a better characterization of diabetic cornea complications (see table 1). Among the articles detailing animal models, the majority either performed intraperitoneal injection of streptozocin (STZ) in mice/rats, modeling type I diabetes or administered high-fat diet in mice, causing diet-induced obesity (DIO) and increased insulin resistance, modeling type 2 diabetes. For other models, two papers used db/db mice, and one paper used Otsuka Long-Evans Tokushima Fatty (OLETF) rats, both which are models of type 2 diabetes.
STZ is a compound that has preferential toxicity toward pancreatic β islet cells. STZ injection was first reported to have diabetogenic properties in 1963 and has since become a chemical widely used to model diabetes in experiments. Briefly for this model, rats are given daily injections of 160–240 mg/kg STZ for 2 days in order to mimic type I diabetes.1 5 The onset of hyperglycemia is rapid. The majority of animals have significantly increased blood glucose level 48 hours after STZ injection, which stabilizes 6–10 days after injection.6 It is an efficient and cost-effective method for experimental use. Evidence from published studies demonstrate that STZ-treated mice have significant diabetic cornea neuropathy, with signs of progressive sub-basal nerve plexus damage, even in the absence of an external insult. While these findings would make STZ-treated rodents excellent models for studying cornea neurotrophic ulcers, these features may also potentially alter epithelial wound-healing outcomes after cornea injury.7 Documented adverse effects of STZ injections include potentially lethal hepatotoxicity and nephrotoxicity. Furthermore, STZ-treated mice have been reported to suffer bladder dysfunction and excessive urination.8 More importantly, STZ-induced diabetic mice are more likely to suffer respiratory distress, significant weight loss and poorer generalized health, resulting in high mortality rates compared with other animal models of diabetes. These factors need to be taken into consideration when using STZ-treated rodents for modeling of diabetes.
This is a model for studying type 2 diabetes. Briefly, mice are fed for 4–30 weeks with chow containing high fat and sugar (mostly sucrose and occasionally fructose). DIO mice are known to develop obesity, dyslipidemia and impaired glucose tolerance.2 DIO mice are primarily used in studies modeling obesity rather than diabetes, and the induction of sustained hyperglycemia is only achieved at 16–20 weeks after initiation of the diet.9 It is also important to note that the hyperglycemia achieved is mild compared with that seen in STZ injections. Depending on the goals and hypothesis of a study, special experimental procedures such as glucose tolerance test, insulin level measurement, insulin tolerance test and body composition measurement are required when DIO mice are used.
Two groups investigating diabetic neuropathy used db/db mice for in vivo experiments.10 11 The db/db mouse is an experimental model for type 2 diabetes with the development of sustained severe hyperglycemia. Db/db mice are genetically obese leptin receptor-deficient mice.10 They develop hyperphagic obesity and non-ketotic diabetes similar to type 2 DM in humans.12 This model has been previously used to study diabetic neuropathy with reported altered nerve and ocular properties compared with controls.10 However, it is important to note that both studies showed that while peripheral neuropathy is present in db/db mice, not all of the structural changes observed in human diabetic retinopathy can be detected using this model.
Nagai et al used OLETF rats to investigate corneal epithelial wound healing over time. Compared with controls, OLETF rats had significantly slower wound healing rates.13 The OLETF rat is an established model for human type 2 DM where the rats develop sustained hyperglycemia and clinical signs of diabetes starting from 25 weeks of age.13 OLETF rats have been used in diabetes research since the 1990s, modeling mild obesity and late onset of hyperglycemia (defined as after 18 weeks of age). It has been reported that the diabetic phenotype more often manifests in male rats compared with their female counterparts.14 The experiments by Nagai et al demonstrated a strong relationship between the cornea wound healing rate constant and plasma glucose level. Aside from glucose level, the rate of wound healing decreased with age in OLETF rats. It is important to note however that unlike diabetes in humans, OLETF rats have an augmented immune response, resulting in an overproduction of proinflammatory cytokines in response to insults compared with controls.15 This would potentially adversely impact diabetic studies investigating changes in immunity.
In vitro models
Cultured human epithelial cells have been used to study corneal epithelial wound healing in health and disease, allowing for an improved understanding in differential gene expression, cell differentiation and various biochemical properties between epithelial cells in glucose-rich media and controls (see table 2). After scratch wound injury, cell proliferation and migration assays are employed to quantify differences between groups.16 17 Cell culture studies allow for improved understanding of disease pathogenesis and molecular mechanism of potential therapeutic agents while avoiding ethical concerns with animal welfare.18–20 However, while the local effects of high glucose levels can be studied using in vitro models, the lack of a blood supply and innervation prevents a more well-rounded and clinically translatable approach to investigating the effect of diabetes on injured corneal epithelial cells.
In order to investigate diabetic corneal neuropathy in vitro, primary trigeminal ganglia (TG) neuronal cells were used for by Dai et al.11 They studied the role of the neuropeptide FF (NPFF) in corneal nerve injury. TG consist of neuronal cells and two types of glial cells: satellite cells and Schwann cells,21 both of which are involved in the pathogenesis of diabetic neuropathy. The protocol for producing dissociated primary sensory neurons is as previously described by Malin et al.22 Neuronal cultures guarantees a tight control of the extracellular environment, which ensures a precise neuronal environment. This is particularly advantageous in the study of the intrinsic electrical properties of neurons and sensory transduction.22
Modeling epithelial injury
Twelve published animal studies induced direct mechanical injury either via a scratch on the corneal epithelium or via corneal epithelial debridement.3 23 Briefly, a corneal epithelial wound, about 2–4 mm diameter, is fashioned using an Algerbrush remover or a blunt scalpel blade under local or general anesthesia. Corneal epithelium debridement has been used as a model to study delayed wound healing24 24 24 24 and recurrent corneal epithelial erosion syndrome.24 25
Two papers have applied alkali burn to the mouse cornea in order to induce injury and inflammation. Compared with cornea epithelial debridement, the recovery time for re-epithelialization after burn is significantly longer,26 with associated ocular surface inflammation.27 Briefly, alkali injury is induced by applying a filter paper, soaked in NaOH solution cut to 2–4 mm diameter for set time period, on the cornea epithelium.28
For both mechanical and chemical injury, antibiotics, such as rapamycin or aureomycin eye ointment, is usually applied daily or regularly after the injury to avoid superimposed cornea infection. For monitoring over time, the epithelial defect size can be visualized by fluorescein strip staining, and the total surface area can be quantified with imaging software, such as the National Institute of Health Image J software. Another method of quantifying corneal injury is corneal opacity scoring29 30 in which the degree of cornea opacity is determined clinically on a numerical scale of 0–4: with 0: clear cornea; 1: mild stromal opacity; 2: moderate stromal opacity; 3: severe corneal opacity with visible iris; and 4: opaque cornea with iris not visible.31
Molecular mechanisms of impaired corneal wound healing in patients with diabetes
Altered protein concentrations
Delayed corneal epithelial wound healing may lead to sight-threatening complications, including ocular surface irregularities, microbial keratitis and corneal scarring.32 The treatment of delayed wound healing in diabetic corneas remains a therapeutic challenge.33
A number of published studies have reported delayed corneal wound healing in the presence of sustained hyperglycemia.34 Various proteinases, growth factors and cytokines that have regulatory effects of inflammation and wound healing process are also shown to be altered locally in DM eyes compared with controls. The proteins thought to be involved in the wound healing process include epidermal growth factor,35 transforming growth factor beta 3, ciliary neurotrophic factor, insulin-like growth factor-136 and matrix metalloproteinase 3 and 10 (MMP-3 and MMP-10).37 38 Furthermore, recent studies have elucidated novel factors involved in delayed corneal epithelial wound healing in diabetes (see table 3).
Yamamoto et al’s study used shotgun liquid chromatography mass spectrometry to detect differentially expressed proteins in the cornea of STZ rats compared with controls.1 The study identified 188 proteins that were expressed at least twofold higher in STZ rats compared with controls and were serving as candidate proteins in the pathogenesis of delayed wound healing in diabetes. By gene ontology analysis, the roles of these proteins identified were further examined. A total of 15 proteins were noted to be differentially expressed in the cornea of STZ rats compared with controls and were determined to be extracellular matrix proteins. In particular, the level of lumican expression in the cornea of STZ rats was significantly higher than that of the normal rats. Yamamoto et al noted that in the cornea of the control rat, the expression level of lumican was elevated during the wound healing process, and it returned to the baseline expression level after the wound was healed completely. However, a high expression level of lumican in the cornea of STZ rats was still maintained even after the wound was healed completely. The authors noted that in experiments, STZ rats had poorer adhesion between basal cells of the cornea epithelium and the underlying Bowman’s membrane during the healing response and thus postulated a role for lumican in its pathogenesis.
Huang et al identified that abnormal occludin expression may contribute to delayed epithelial wound healing in diabetic corneas.3 Occludin is an important component of tight junctions (TJs) in the cornea epithelium. It has been identified as a target for signaling events and involved in regulating paracellular permeability.39 Huang et al used 100 Sprague-Dawley male rats for experiments and induced diabetes in half of them using a combination of HFD and STZ injection. Would healing after epithelial debridement was documented and compared between groups using fluorescein staining, H&E staining and scanning electron microscopy. Immunofluorescence and Western blot analysis demonstrated that occludin expression in the corneal epithelium of the diabetic group was weaker compared with the normal group at the 16 and 48 hours time-points after debridement. This corresponded with a slower wound healing rate in diabetic mice compared with controls.
Altered inflammatory response
Royer et al40 first reported that corneal epithelial cells exhibited myeloid characteristics. They were found to express lymphocyte antigen 6 complex locus G6D, C-C chemokine receptor type 2 and CX3C chemokine receptor 1. Particularly, Ly6C+ cells are found to function as antigen presenting cells. This means that the cornea epithelium serves as the first line of immunity in the ocular surface after insult.
Neutrophils are early responders in the inflammatory process and play an important role in the cornea wound healing process after epithelial debridement.41 Natural killer cells are part of the innate immune system, and its main role is to kill aberrant cells and to assist in the function of cytotoxic T lymphocytes.42 Yan et al reported that both neutrophil and natural killer (NK) cell infiltration were reduced during wound closure in diabetic corneas compared with controls.43 This was associated with a lower level of the secreted form of IL-1 receptor antagonist (sIL-1Ra) in diabetic corneas compared with controls. IL-1β and its receptor IL-1a are important mediators of the wound healing response. It has been shown to enhance infiltration of neutrophils and NK cells after injury and also promotes corneal regeneration. In the normal cornea, both IL-1β and sIL-1Ra are increased in response to wounding. The findings of this study suggest an important role for reduced IL-1Ra secretion in the pathogenesis of diabetic cornea wound healing.
Altered nerve signaling
Diabetes is a major cause of peripheral nerve damage. Diabetes alters corneal nerve structure44 and downregulate the release of neuropeptides, neurotrophins and growth factors.45 Kneer et al2 reported a significant decrease in cornea sub-basal nerve density in DIO mice compared with controls, demonstrating similar established phenotypes to that of human diabetics. In this study, a DIO mouse model of type 2 diabetes was used to characterize changes in sensory nerves and P2X purinoceptor 7 (P2×7). This is a trimeric ATP-gated cation channel expressed in a number of tissues. It serves as a pain receptor. Kneer et al2 previously reported that P2×7 mRNA was significantly overexpressed in diabetic human corneas compared with controls. Therefore, the authors hypothesized that the P2×7 receptor acts to sense changes at the leading edge following an epithelial abrasion, with this form of regulation lost in diabetic eyes.
The NPFF is an octapeptide that has been implicated in a wide variety of physiological functions in the brain.46–48 Dai et al11 found using real-time polymerase chain reaction (RT-PCR) that NPFF expression was significantly lower in the trigeminal ganglion (TG) tissues of type 2 diabetic db/db mice compared with controls. The team further demonstrated that NPFF enhanced neurite elongation in diabetic TG neurons in vitro, thereby implicating its deficiency in the pathogenesis of diabetic corneal neuropathy. When delivered via subconjunctival route, NPFF promoted corneal nerve injury recovery and epithelial wound healing in db/db mice. This effect could be completely abolished with the addition of RF9, a selective NPFF receptor antagonist. NPFF is thus a potential neuroregenerative factor in the treatment of diabetic corneal neuropathy.
Substance P (SP) is a nociceptive neurotransmitter, primarily released from sensory nerve fibers and also immune cells, including macrophages, eosinophils, lymphocytes and dendritic cells, in response to injury.49 SP exhibits potent proinflammatory effects in immune and epithelial cells and participates in the pathogenesis of various inflammatory diseases. It is known to have positive effect on corneal epithelial wound healing. Yang et al investigated the potential therapeutic effects of SP on hyperglycemia-induced delayed corneal wound healing in vitro and in vivo. SP application promoted epithelial wound healing, recovery of corneal sensation, improvement of mitochondrial function and increased reactive oxygen species (ROS) scavenging capacity in vivo and in vitro.16 The promotion of SP on diabetic corneal epithelial healing was completely abolished by a neurokinin-1 (NK-1) receptor antagonist. Moreover, the subconjunctival injection of NK-1 receptor antagonist also caused diabetic corneal pathological changes in normal mice suggesting a role for SP deficiency in the pathogenesis of diabetic cornea neuropathy.
Potential treatments for delayed corneal wound healing in patients with diabetes
A number of studies investigated the potential efficacy of novel therapeutic agents for diabetic keratopathy. The treatments include Resolvin D1 (RvD1), safflower extract and aceglutamide (SA) injection, the synergy peptide Pro-His-Ser-Arg-Asn (PHSRN), pigment epithelium-derived factor (PEDF), Serpine 1 and aloe vera (AV) (see table 4).
Li et al50 explored the effects of SA in treating diabetic cornea neuropathy. A physical injury was induced on the central part of the cornea of STZ mice and controls. Following injury both groups were given SA intraperitoneally for 21 days. Compared with controls, the diabetic cornea had a lower density of cornea nerve fibers at baseline. Treatment with SA promoted cornea secretion of vascular endothelial growth factor-B (VEGF-B), nerve growth factor (NGF) and Glial cell line-derived neurotrophic factor (GDNF) and increased cornea nerve fiber density. Furthermore, the beneficial effects of SA were shown to be completely abolished by inhibition of the VEGF-B receptor.
Morishige et al51 discovered that topical administration of fibronectin-derived peptide PHSRN greatly facilitated healing of corneal epithelial wounds in diabetic rats. The PHSRN sequence is one of the cell-binding sites for fibronectin and has been previously reported to promote corneal epithelial cell migration.52 As an eye-drop, PHSRN was demonstrated to be effective at a minimum concentration of 2 mM and has the greatest efficacy at a concentration of 200 mM. The study also reported that PHSRN facilitated corneal wound healing in both diabetic mice and controls.51
AV is a perennial succulent belong to the Lily (Liliaceae) family. Reported therapeutic use of AV include promoting wound healing, attenuating inflammatory response, antibacterial, antioxidant, antiviral and antifungal actions, as well as antidiabetic activities.53 Atiba et al28 used a corneal alkali-burn injury model on STZ-treated rats to study the efficacy of topically applied AV on diabetic corneal wound healing. The investigators demonstrated the efficacy of topical AV in enhancing corneal re-epithelialization rate and reducing ocular surface inflammation after alkali burn in diabetic rats.
Known as a proresolving mediator, RvD1 has been widely investigated in studies of various diseases, such as arthritis, pulmonary disease and kidney injury.54 Zhang et al23 reported that topical administration of RvD1 significantly promoted corneal epithelial wound healing, reactivated epithelial regeneration-related signaling pathways and sped up resolution of corneal inflammation. Additionally, RvD1 treatment promoted regeneration of diabetic corneal nerves and restored corneal mechanical sensation in STZ-treated mice. Increased oxidative stress in the corneal epithelium has been identified as part of the diabetic complications exhibited on the ocular surface.55 The presence of advanced glycation end products in diabetes increases the generation of intracellular ROS
in human cornea epithelial cells.56 Zhang et al23 further demonstrated that topical administration of RvD1 reduces AGE-mediated ROS accumulation and NADPH oxidase 2/4 overexpression in human cornea epithelial cells in vitro.
He et al57 demonstrated that topical treatment with PEDF, in combination with docosahexaenoic acid (DHA), promotes corneal nerve regeneration and wound healing in diabetic mice. After administration of pigment epithelium-derived factor and docosahexaenoic acid (PEDF+DHA), elevated corneal sensitivity and increased tear production was observed. Additionally, PEDF+DFA also selectively recruited type 2 macrophages and prevented neutrophil infiltration in diabetic wounded corneas. Meanwhile, the regenerated nerves were shown to be functional, as demonstrated by the restoration of corneal sensitivity, tear volume increase and upregulated expression of the sensory neuropeptide SP.
Serpine1 is a serine protease inhibitor that functions as the principal inhibitor of tissue and urokinase plasminogen activator (uPA). It was reported by Sun et al that Serpine1 expression is upregulated during cornea injury, and this response was found to be significantly suppressed in diabetic corneas compared with controls. For diabetic corneas, the addition of exogenous Serpine1 significantly accelerated wound healing and modulated local proteolytic enzymatic activities, including that of MMP-3. Sun et al58 suggested that early intervention with systemic and local therapies modulating Serpine1 and/or uPA proteolytic activities may provide hope for preventing sight-threatening complications in diabetic cornea disease.
Advantages and limitations of current models for diabetic corneal wound healing
The diversity of current models for diabetes allows for presentations of DM with more than one model, thus corresponds to the diversity of clinical manifestations of DM. However, certain disadvantages are also present. Injected chemicals that induced diabetes in rodent are suspected to have detrimental effects on other organs. Particularly, STZ was reported to cause lymphopenia and a relative increase in T-regulatory cells, which may interfere with studies regarding systemic immunity.59 Despite the rapid onset of diabetes brought by STZ administration, this model of diabetes has reported detrimental effects on multiple organs6; in severe cases death can result from multiorgan failure. DIO mice and OLETF rats are more commonly used in studies of type 2 diabetes, obesity-induced metabolic disorders and diabetic complications.60 Aside from those used in reported studies, other animal models could be used for future experiments in diabetic cornea wound healing, including mice heterozygous for the Akita spontaneous mutation (Ins2Akita). This a model of type I diabetes, with heterozygous Ins2Akita mice developing hyperglycemia, hypoinsulinemia, polydipsia and polyuria by 3–4 weeks of age. As such this is an excellent model for studying diabetic microvascular and macrovascular complications.
A cornea epithelial cell culture system is an excellent model for testing the local therapeutic effects of topical drugs as well as their pharmacokinetic properties.61 Additionally, in vitro studies are particularly important for molecular studies into disease pathogenesis and resolution. Despite the added advantages of the sparing of animals for research work, in vitro studies are still limited by their inability to properly model the complex interactions between cells and tissues in the human eye, as well as the important roles the nerve and blood supply play in the disease. Furthermore, the cornea, being an exposed organ, is constantly interacting with the ocular adnexa, for example, during blinking, and the external environment. These factors remain difficult to model in vitro.61 The engineering of multicellular coculture systems, the so-called cornea-on-a-chip, may provide a better platform for in vitro studies in the future.
Although in vivo model provides understanding of diabetic neuropathy on a physiological and cellular level, the availability of cell culture model is also imperative in presenting details of the molecular events that might be obscured in animal study. TG neuronal cells were mentioned earlier as one in vitro model in studying corneal nerve injury associated with hyperglycemia.11 Other reported usage of primary cultures in studying diabetic neuropathy include dorsal root ganglia cells, Schwann cells and cortical neurons, yet they are likely to become heterogeneous due to presence of contaminating and highly proliferating fibroblasts and survive only limited passages.62 These drawbacks can be circumvented by various experimentally-proved robust transformed cell lines.62 In studies of impaired corneal innervation, the usage of in vitro model is relatively scarce. However, previous results of in vitro studies have indicated the functions of corneal nerve fibers in promoting corneal wound healing and maintaining normal physiology of the cornea.63
Translatability to clinical practice
In this review, a number studies have reported potential treatment strategies of diabetic corneal diseases, such as AV, RvD1, SA injection and topical administration of PEDF or combined administration of PEDF+DHA.23 28 50 51 58 Among them, most of the studied drugs can be administered topically as eye-drops. Particularly, AV is already widely accepted and used as a dietary supplement and in complementary medicine.
Aside from the mentioned therapeutic studies, a number of molecular alterations found in diabetic cornea indicates possible future drug targets in treating delayed corneal wound healing. They include targets involved in cell–cell adhesion, nerve regeneration and signaling and immunomodulation. As a link between altered immune response, cornea inflammatory cell invasion and cornea sub-basal nerve plexus damage have been demonstrated in studies on human diabetics, there is promise that these therapeutic targets are complementary and will be translatable to future clinical practice.64 Previous studies have demonstrated the role of lumican in ocular diseases, immune response and wound healing.65 Lumican is critical in maintaining the corneal collagen structure that ensures corneal transparency.66 Given the multiple functions of lumican on the ocular surface, it is worthy to be considered as a target in treating diabetic corneal complications and restoring corneal clarity. Occludin is one component of the TJs present in the apical layer of the epithelium. It plays a crucial role in maintaining the barrier function of the corneal epithelium to protect the endothelium from the external environment. Novel findings of the effect of abnormally expressed occludin in diabetic corneas further suggests that it can potentially be a target of drug delivered at the ocular surface. The discoveries of NPFF as a potential neuroregenerative factor11 and SP’s role in promoting corneal wound healing16 serve as promising areas for drug development. Neuropeptides possess broad spectrum of functions from neurohormone and neurotransmitter to growth factors and inflammatory mediators.67 Previous reports have highlighted the effects of neuropeptides on corneal epithelial cell growth, proliferation and differentiation.63
The main concern with making use of the described therapeutic targets in actual practice is the difficulty in developing topical treatments for the abnormal processes. This is especially a problem for proteins involved in cell–cell adhesion, as they are secreted by the diseased cornea epithelial cells and cannot be replaced externally. Treatments may thus require genetic modifications and gene silencing techniques. Thus, neuropeptides, including NPFF and SP, may provide a more readily translatable form of treatment in terms of direct topical application on cornea wounds.
Keratopathy is a common and sight-threatening complication of diabetes, manifesting with delayed cornea wound healing, recurrent corneal erosion syndrome and neurotrophic ulcers. While there is significantly less attention to diabetic keratopathy compared with retinal complications, the cornea is the most superficial part of the eye and thus most accessible for research and treatment. The clinical manifestations of diabetic keratopathy involve a complex interplay between the cornea epithelial cell lining, ocular surface immunity and cornea sub-basal nerve plexus. Due to the recent availability of robust in vivo and in vitro models of diabetic cornea wound healing, we now have an improved understanding of the diabetic keratopathy pathogenesis and progression. These studies have provided novel targets for future preventive and therapeutic strategies. Furthermore, studies have used these models as a platform for testing novel therapeutic agents, with the close approximation between available in vivo models and human corneas allowing for early translation of results into clinical trials. This review highlights the continued importance of experimental modeling in solving sight-threatening complications of the eye.
Contributors All authors attest that they meet the current ICMJE criteria for authorship. YB and KCS were involved in study design, data collection, data analysis, manuscript writing and editing. SSK, YKC, AC-YL, TCYC, VJ and LT were involved in data collection, data analysis, manuscript writing and editing.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement There are no data in this work.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.